

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

David N. Springer¹, Michael Bauer¹, Iris Medits¹, Jeremy V. Camp¹, Stephan W. Aberle¹, Clemens Burtscher², Eva Höltl^{2,3}, Lukas Weseslindtner¹, Karin Stiasny^{1,4,*}, Judith H. Aberle^{1,4,*}

1 Center for Virology, Medical University of Vienna, Austria

2 Health Center Erste Bank, Erste Bank, Vienna, Austria

3 Center for Public Health, Medical University of Vienna, Austria

4 These authors contributed equally.

* Correspondence to karin.stiasny@meduniwien.ac.at and judith.aberle@meduniwien.ac.at.

Keywords: Bivalent COVID-19 booster vaccine, neutralizing antibodies, Omicron Breakthrough infection

Abstract

We report SARS-CoV-2 neutralizing antibody titers in sera of triple-vaccinated individuals who received a booster dose of an original monovalent or a bivalent BA.1- or BA.4/BA.5-adapted vaccine, or had a breakthrough infection with Omicron variants BA.1, BA.2 or BA.4/BA.5. A bivalent BA.4/BA.5 booster or Omicron-breakthrough infection induced increased Omicron-neutralization titers compared with the monovalent booster. The XBB.1.5 variant effectively evaded neutralizing-antibody responses elicited by current vaccines and/or infection with previous variants.

29

30 **Text**

31 The SARS-CoV-2 Omicron variant (B.1.1.529) evolved into several sublineages (BA.1 to BA.5, their
32 descendants and recombinant forms), carrying mutations in the spike protein that result in escape from
33 neutralizing antibodies elicited by ancestral vaccines¹. Since late 2022, bivalent COVID-19 mRNA-
34 booster vaccines, containing equal amounts of mRNAs encoding the ancestral (Wuhan-1) or Omicron
35 spike proteins (BA.1 or BA.4/BA.5), are in widespread use. It is, however, still unclear whether a
36 single booster dose with a bivalent vaccine would enhance neutralization of Omicron variants beyond
37 that of original vaccines.

38 We investigated serum neutralization of SARS-CoV-2 variants after a bivalent BA.1 (n=12) or
39 bivalent BA.4/BA.5 (n=22) booster of individuals who had previously received three vaccine doses.
40 As reference cohorts, we included vaccinees with one (n=31) or two booster doses (n=26) of the
41 original monovalent mRNA vaccine. Sera were collected 20-31d (bivalent-BA.1), 21-30d (bivalent-
42 BA.4/BA.5), 15-43d (three-dose monovalent) and 16-38d (four-dose monovalent) after vaccination
43 (Supplementary Tables 1 and 2). All specimens were nucleocapsid-antibody negative, indicating that
44 these individuals had no previous SARS-CoV-2 infection. Serum-neutralizing activity was determined
45 in a well-characterized live-virus neutralization test (NT)², using SARS-CoV-2 wildtype (wt, D614G
46 virus), Delta and Omicron variants (BA.1, BA.2, BA.5, XBB.1.5). We found for all cohorts that NT
47 titers were highest against D614G (Figure 1a). The bivalent-BA.4/BA.5 booster induced significantly
48 higher neutralization titers to BA.5 than the three- and four-dose monovalent boosters (Figure 1a).
49 Consistent with our data, there is epidemiological evidence indicating that bivalent vaccines provide
50 significant additional protection against symptomatic Omicron infection and hospitalization^{3, 4}. Of
51 note, our results showed only modestly increased BA.5 neutralization, which is in agreement with
52 previous studies⁵⁻¹², whereas others suggested that the bivalent-BA.4/BA.5 vaccine would not be more
53 effective than the original monovalent vaccine¹³⁻¹⁵. The bivalent-BA.1 booster induced similarly high
54 neutralization titers as the bivalent-BA.4/BA.5 booster (Figure 1a), but significant differences were
55 not observed relative to the monovalent vaccine, which is in line with previous studies⁶. XBB.1.5-NT
56 titers were lowest in all groups (Figure 1a), which confirms the strong escape of this variant from
57 current vaccine- and infection-elicited neutralizing antibodies^{8, 9, 16}.

58 A comparison of NT titers between sera obtained on the day of booster and those one month later
59 showed that the bivalent-BA.1 vaccine yielded the strongest increase in BA.1-NT titers (Figure 1b).
60 Similarly, the enhancement of NT titers of the bivalent-BA.4/BA.5 booster sera was greatest against
61 BA.4/BA.5 (Figure 1b), indicating that variant-specific neutralizing antibodies were elicited by both
62 bivalent vaccines.

63 We next analyzed sera from individuals after breakthrough infection with Omicron BA.1 (n=11), BA.2
64 (n=7) or BA.4/BA.5 (n=10) variants, following 2-4 doses of mRNA vaccination. Sera were obtained

65 13-36d, 16-25d and 22-52d after infection, respectively (Supplementary Table 3). NT titers after
66 breakthrough infection were higher than after vaccination of SARS-CoV-2-naive individuals.
67 BA.4/BA.5-breakthrough infections elicited significantly higher BA.5-NT titers than BA.1-
68 breakthrough infections (Figure 1c). As for the vaccinees, XBB.1.5-NT titers were the lowest in all
69 breakthrough cohorts (Figure 1c).

70 We used the NT titers (Figure 1) to generate antigenic maps that depict antigenic distances between all
71 tested variants (Figure 2a). Variant distribution was similar for three- and four-dose-monovalent
72 vaccine sera, with the highest reactivity around D614G, whereas the distance to BA.5 was
73 approximately four antigenic units, equivalent to an 8-fold difference in neutralization (Figure 2).
74 These data are in agreement with studies using post-vaccination sera with similar distributions of pre-
75 Omicron and Omicron variants^{11, 17}. The bivalent vaccine sera and Omicron-breakthrough infection
76 sera yielded antigenic maps in which pre-Omicron and Omicron BA.1, BA.2 and BA.5 variants
77 clustered tightly together, indicating increased neutralization breadth. Omicron XBB.1.5 mapped the
78 furthest from the D614G strain, and the distance to XBB.1.5 was highest for monovalent booster sera
79 (up to 5.5 antigenic units), followed by bivalent-BA.1 booster sera, and lowest for the bivalent-BA.5
80 booster sera (4 antigenic units). Additionally, we analyzed cumulative antigenic distance scores
81 calculated from the sum of antigenic units between D614G and each variant measured for each serum
82 (Figure 2b). In comparison to the monovalent vaccine sera, and consistent with the antigenic maps,
83 these scores were significantly lower for bivalent-BA.1 and BA.4/BA.5 vaccine and breakthrough
84 post-infection sera (Figure 2b). These data indicate that neutralizing activities were broader after
85 bivalent BA.1 or BA.4/BA.5 boosters than after monovalent boosters.

86 Our study has several limitations: First, the sample size was relatively small with some differences
87 among study groups (Supplementary Tables 1-3), including (i) unequal numbers of vaccine doses, i.e.,
88 more participants with 4 doses among the BA.4/BA.5-breakthrough-infection cohort; (ii) some
89 participants in the bivalent but not in the monovalent cohort had received vector vaccines as a first
90 dose; (iii) more female than male participants in monovalent (3-dose) vs. bivalent vaccine groups.
91 Second, we did not measure non-neutralizing antibodies and cellular responses that are likely involved
92 in durable protection against severe COVID-19, with T cell responses being highly cross-reactive
93 against Omicron and prior variants¹. Third, we do not know how NT titers relate to protection against
94 infection, severe disease and death^{1, 18}.

95 In summary, our data show that a bivalent booster elicits broader Omicron-neutralizing activities and
96 are concordant with recent real-world data demonstrating superior protection against severe disease by
97 BA.5-bivalent booster vaccines³. Moreover, our data support the conclusion that the recently emerged
98 XBB.1.5 variant effectively evades neutralizing-antibody responses elicited by current vaccines or
99 breakthrough infection with previously circulating variants.

101 **METHODS**

102 **Omicron variant identification**

103 Nasopharyngeal swabs were analyzed with the mutation assays VirSNiP SARS-CoV-2 Spike S371L
104 S373P, VirSNiP SARS-CoV-2 Spike 484A 486V and VirSNiP SARS-CoV-2 Spike L452R (TIB
105 MOLBIOL, Berlin, Germany). Characteristic melting peaks for the mutations S371L & S373P
106 indicated an infection with Omicron BA.1, S371F & S373P indicated BA.2, and S371F & S373P with
107 the additional mutations L452R & F486V indicated BA.4/5, respectively.

108 **SARS-CoV-2 neutralization test (NT)**

109 SARS-CoV-2 strains were isolated from nasopharyngeal swabs of infected individuals using Vero E6
110 (ECACC #85020206) or Vero E6-TMPRSS2 cells (kindly provided by Anna Ohradanova-Repic), as
111 described previously². Sequences determined by next-generation sequencing were uploaded to the
112 GSAID database (wt, B.1.1 with the D614G mutation:EPI_ISL_438123; Delta, B.1.617.2-like, sub-
113 lineage AY.122:EPI_ISL_4172121; Omicron, B.1.1.529+BA.*, sub-lineage
114 BA.1.17:EPI_ISL_9110894; Omicron, B.1.1.529+BA.*, sublineage BA.2:EPI_ISL_11110193;
115 Omicron, B.1.1.529+BA.*, sub-lineage BA.5.3:EPI_ISL_15982848; XBB.1.5:EPI_ISL_17062381.
116 Pango lineages were determined with Pango v.4.1.3, Pango-data v1.17.).

117 Live-virus NTs were performed as previously described². Serial two-fold dilutions of heat-inactivated
118 serum (duplicates) were incubated with 50-100 TCID₅₀ SARS-CoV-2 for 1h at 37°C. The sample-
119 virus mixtures were added to Vero E6 cells and incubated for three to five days at 37°C. NT titers
120 were expressed as the highest reciprocal serum dilution that prevented cytopathic effect, which was
121 assessed microscopically. NT titers ≥ 10 were considered positive.

122 **Antigenic cartography**

123 We constructed antigenic maps based on serum-neutralization data with antigenic cartography^{11,17}.
124 The position of the variants and sera corresponds to the fold-difference to the maximum titer for each
125 serum. A grid unit in any direction (one antigenic unit) represents a two-fold change in neutralization
126 titer. Antigenic maps were generated with the Racmacs package (<https://github.com/acorg/Racmacs>)¹⁹
127 in R with 500 optimization steps and the minimum column basis parameter set to 'none'.

128 **Ethics**

129 All work was conducted in accordance with the Declaration of Helsinki in terms of informed consent
130 and approval by an appropriate institutional board. Written informed consent from study participants
131 was not required, as the analysis was performed on anonymized leftover samples from routine
132 laboratory diagnosis in accordance with national legislation and institutional requirements. The ethics
133 committee of the Medical University of Vienna, Austria, approved the study protocol (EK1035/2016,
134 EK1513/2016, EK1926/2020, EK1291/2021).

135 Statistical analyses

136 Statistical analysis was performed with Graphpad Prism 9.3.1 and R 4.2.0. Kruskal-Wallis test (two-
137 tailed) with Dunn's multiple comparison correction was used to compare NT titers and cumulative
138 antigenic distance scores between different cohorts. For medians and fold-changes of pre- and post-
139 vaccination titers, values <10 were set to 5. Wilcoxon's signed-rank test followed by Bonferroni
140 correction was used to compare paired data. Alpha was set to 0.05.

141 REFERENCES

- 142 1. Barouch, D.H. Covid-19 Vaccines - Immunity, Variants, Boosters. *N Engl J Med* **387**, 1011-
143 1020 (2022).
- 144 2. Medits, I. *et al.* Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1
145 and BA.2 Infections. *Front Immunol* **13**, Article 946318 (2022).
- 146 3. Lin, D.Y. *et al.* Effectiveness of Bivalent Boosters against Severe Omicron Infection. *N Engl J*
147 *Med* **388**, 764-766 (2023).
- 148 4. Link-Gelles R, C.A., Fleming-Dutra KE, *et al.* Effectiveness of Bivalent mRNA Vaccines in
149 Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing
150 Program, United States, September–November 2022. *MMWR Morb Mortal Wkly Rep*
151 *2022;71:1526–1530* (2022).
- 152 5. Addetia, A. *et al.* Therapeutic and vaccine-induced cross-reactive antibodies with effector
153 function against emerging Omicron variants. *bioRxiv* (2023).
- 154 6. Chalkias, S. *et al.* A Bivalent Omicron-Containing Booster Vaccine against Covid-19. *N Engl*
155 *J Med* **387**, 1279-1291 (2022).
- 156 7. Davis-Gardner, M.E. *et al.* Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA
157 Bivalent Booster. *N Engl J Med* (2022).
- 158 8. Jiang, N. *et al.* Bivalent mRNA vaccine improves antibody-mediated neutralization of many
159 SARS-CoV-2 Omicron lineage variants. *bioRxiv*, 2023.2001.2008.523127 (2023).
- 160 9. Kurhade, C. *et al.* Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and
161 XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. *Nat Med* **29**, 344-347 (2023).
- 162 10. Qu, P. *et al.* Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5,
163 CH.1.1 and CA.3.1 Variants. *bioRxiv*, 2023.2001.2016.524244 (2023).
- 164 11. Wang, W. *et al.* Antigenic cartography of well-characterized human sera shows SARS-CoV-2
165 neutralization differences based on infection and vaccination history. *Cell Host Microbe* **30**,
166 1745-1758 e1747 (2022).
- 167 12. Zou, J. *et al.* Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and
168 XBB.1 with Bivalent BA.4/5 Vaccine. *bioRxiv*, 2022.2011.2017.516898 (2022).
- 169 13. Hoffmann, M. *et al.* Effect of hybrid immunity and bivalent booster vaccination on omicron
170 sublineage neutralisation. *Lancet Infect Dis* **23**, 25-28 (2023).
- 171 14. Wang, Q. *et al.* Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. *New Engl J*
172 *Med* (2023).
- 173 15. Collier, A.Y. *et al.* Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters. *N Engl J Med*
174 **388**, 565-567 (2023).
- 175 16. Hoffmann, M. *et al.* Profound neutralization evasion and augmented host cell entry are
176 hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5. *Cell Mol Immunol*, 1-4
177 (2023).
- 178 17. van der Straten, K. *et al.* Antigenic cartography using sera from sequence-confirmed SARS-
179 CoV-2 variants of concern infections reveals antigenic divergence of Omicron. *Immunity* **55**,
180 1725-1731 e1724 (2022).
- 181 18. Krammer, F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nat Med*
182 **27**, 1147-1148 (2021).
- 183 19. Wilks, S.H. *et al.* Mapping SARS-CoV-2 antigenic relationships and serological responses.
184 *bioRxiv*, 2022.2001.2028.477987 (2022).

185

186 **FIGURE LEGENDS**

187 **Fig. 1 Serum-neutralizing activity against SARS-CoV-2 variants of vaccinated or**
188 **breakthrough-infection cohorts.** (a) NT titers of sera from individuals 3-4 weeks after a third or
189 fourth dose of monovalent mRNA vaccines (V1/V2/V3-monovalent, V1/V2/V3/V4-monovalent), or
190 bivalent-BA.1- or BA.4/BA.5-based mRNA vaccines (V1/V2/V3/V4-bivalent-BA.1, V1/V2/V3/V4-
191 bivalent-BA.5). (b) NT titers at baseline (day 0, pre-V4) and after bivalent-BA.1 or BA.4/BA.5
192 booster vaccination (3-4 weeks, post-V4). (c) NT titers of sera from individuals with breakthrough
193 infection with Omicron BA.1, BA.2 or BA.4/BA.5, following 2-4 doses of mRNA vaccines. Boxes
194 range from 25th to 75th percentile, whiskers show min and max, and horizontal lines the median. BTI,
195 breakthrough infection. NT titers were compared with Kruskal-Wallis test with Dunn's multiple
196 comparison correction. Paired data were analyzed with Wilcoxon's signed-rank test followed by
197 Bonferroni correction. *** $p < 0.001$, ** $p < 0.01$.

198 **Fig. 2 Antigenic maps and cumulative distance scores of SARS-CoV-2 variants for vaccinated**
199 **and breakthrough-infection cohorts.** (a) Antigenic maps of SARS-CoV-2 variants based on post-
200 vaccination (V1/V2/V3-monovalent, $n=31$; V1/V2/V3/V4-monovalent, $n=26$; V1/V2/V3/V4-bivalent-
201 BA.1, $n=12$; V1/V2/V3/V4-bivalent-BA.5, $n=22$) and Omicron breakthrough-infection sera, including
202 subvariants BA.1, BA.2 and BA.4/BA.5 ($n=22$). Squares represent individual sera, circles SARS-CoV-
203 2 variants. The x- and y-axes of the maps are antigenic distances, and each square represents a two-
204 fold change in neutralization titer. (b) Cumulative antigenic distance scores. Boxes range from 25th to
205 75th percentile, whiskers show min and max, and horizontal lines the median. BTI, breakthrough
206 infection. Scores were compared with Kruskal-Wallis tests with Dunn's multiple comparison
207 correction. **** $p < 0.0001$, *** $p < 0.001$.

208

209 **DATA AVAILABILITY**

210 The datasets generated during and/or analyzed during the current study are available from the
211 corresponding authors on reasonable request.

212 **ACKNOWLEDGEMENTS**

213 We thank Jutta Hutecek, Sylvia Malik, Barbara Dalmatiner, Katja Prüger and Elke Peil for their
214 excellent technical assistance.




215 **AUTHOR CONTRIBUTIONS**






216 JA, KS: conceptualization. JA, KS, DS: writing of the manuscript. KS, JA, JC, SA, LW, DS, MB, IM:
217 methodology and experimental work. JA, KS, LW, EH, CB: resources. DS, MB, KS: data analysis.

218 JA: funding acquisition. KS and JA: supervision. All authors contributed to the manuscript and
219 approved the submitted version.

220 **COMPETING INTEREST**

221 The authors have no competing interests to declare.



a**V1/V2/V3-monovalent****V1/V2/V3/V4-monovalent****Omicron-BT1****V1/V2/V3/V4-bivalent-BA.1****V1/V2/V3/V4-bivalent-BA.5****b**